China Neurogenomics Market to Reach $562.1 Million by 2031
Meticulous Research®—a
leading global market research company, published a research report
titled ‘China Neurogenomics Market—Opportunity Analysis & Industry
Forecasts to 2031’. According to this latest publication from Meticulous
Research®, the China neurogenomics market is expected to reach $562.1
million by 2031, at a CAGR of 19.4% from 2024 to 2031.
Reducing sequencing
costs, the rising prevalence of neurological conditions, the increasing use of
advanced sequencing technologies in disease diagnostics & precision
medicine, growing pharmaceutical R&D spending, improving regulatory &
reimbursement scenarios for gene sequencing, growing healthcare spending,
increasing research funding, the rising need to promptly detect & prevent
neurological diseases, advances in neurogenomics products, and government
initiatives encouraging the utilization of sequencing in clinical &
research applications are factors driving the growth of the China neurogenomics
market. However, market growth is restrained by the high costs of
neurogenomics products, low chances for the identification of positive
actionable mutations for precision medicine, and legal and ethical issues
related to sequencing-based diagnoses.
In addition, the
growing adoption of targeted therapies, emerging countries, and growing
awareness about neurological conditions are expected to generate growth
opportunities for market players. However, the changing regulatory
landscape, the limited sequencing capabilities & expertise of small &
medium-sized labs, the lack of sequencing professionals in the country, and the
high capital investment requirements of sequencing setups are prominent
challenges impacting the growth of the China neurogenomics market.
Key Players:
The China
neurogenomics market is moderately competitive due to the presence of many
large and small-sized global, regional, and local players. The key players
operating in the China neurogenomics market are Illumina, Inc. (U.S.), Thermo
Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN
N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.),
Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.),
Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China). The
China neurogenomics market is segmented based on offering, application, and end
user.
Among the offerings
studied in this report, in
2024, the Next-generation Sequencing (NGS) segment is anticipated to dominate
the China neurogenomics market, with a share of 64.1%. The
high prevalence of neurological disorders, large-scale initiatives to advance
diagnosis and treatment approaches using NGS, and rising healthcare
expenditures are factors contributing to the segment’s dominant position in the
China neurogenomics market. Moreover, this segment is also expected to witness
the fastest growth during the forecast period.
Among the
applications studied in this report, in 2024, the research applications segment is anticipated to dominate
the China neurogenomics market, with a share of 61.4%. High
investments in genomics research, rapid adoption of advanced solutions,
including NGS, PCR, and microarrays among academic & research institutes,
and the growing demand for personalized medicine are factors contributing to
the segment’s dominant position in the China neurogenomics market. Moreover,
this segment is also expected to witness the fastest growth during the forecast
period.
Among the end users
studied in this report, in
2024, the pharmaceutical & biotechnology companies segment is anticipated
to dominate the China neurogenomics market, with a share of 44.5%. High
R&D spending of pharmaceutical & biotechnology companies, which drives
the adoption of advanced solutions such as next-generation sequencing
solutions, microarrays, and PCR solutions, and the high incidence of
neurological disorders are factors contributing to the segment’s dominant
position in the China neurogenomics market. However, the academic &
research institutes segment is expected to witness the fastest growth during
the forecast period.
Download Sample
Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=6003
Key Questions
Answered in the Report:
- What is the revenue generated from the
sales of neurogenomics solutions in China?
- At what rate is the demand for
neurogenomics solutions projected to grow in China for the next five to
seven years?
- What are the historical market size and
growth rate for the China neurogenomics market?
- What are the major factors impacting the
growth of this market?
- What are the major opportunities for
existing players and new entrants in the market?
- Which offering, application, and end-user
segments are expected to create major traction for the players in this
market?
- Who are the major players in the China
neurogenomics market? What are their specific product offerings in this
market?
- What are the recent developments in the
China neurogenomics market? What are the impacts of these strategic
developments?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment